// App-Quantinova.ai

1094 : Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).

Researchers

Presenter

  • Zachary William Neil Veitch

Principal Investigators

  • David W. Cescon

  • Sawako Elston

  • Scott Lien

  • Cindy Yang

  • Ben X Wang

  • Hal K. Berman

  • Marcus O. Butler

  • Eitan Amir

  • Christine Elser

  • Sevan Hakgor

  • Amanda Giesler

  • Trevor John Pugh

  • Pamela S Ohashi

  • Lillian L. Siu

  • Philippe L. Bedard

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Princess Margaret - University Health Network, Toronto, ON, CA

  • Department of Pathology and Laboratory Medicine, University Health Network, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Mount Sinai Hospital, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Circulating DNA

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02644369

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved